Vaxxinity (VAXX) Competitors $0.0002 0.00 (0.00%) (As of 11:50 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends VAXX vs. NAVB, CALA, SCPS, AMPE, ARDS, STAB, CMRA, EVLO, GNCA, and EFTRShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Navidea Biopharmaceuticals (NAVB), Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Genocea Biosciences (GNCA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Navidea Biopharmaceuticals Calithera Biosciences Scopus BioPharma Ampio Pharmaceuticals Aridis Pharmaceuticals Statera Biopharma Comera Life Sciences Evelo Biosciences Genocea Biosciences eFFECTOR Therapeutics Vaxxinity (NASDAQ:VAXX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk. Does the MarketBeat Community believe in VAXX or NAVB? Vaxxinity received 5 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 38.46% of users gave Vaxxinity an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% Navidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes64100.00% Which has higher earnings and valuation, VAXX or NAVB? Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinity$70K0.36-$56.93M-$0.450.00Navidea Biopharmaceuticals$70K1.43-$15.18M-$0.06-0.02 Which has more risk and volatility, VAXX or NAVB? Vaxxinity has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Do insiders and institutionals believe in VAXX or NAVB? 83.0% of Vaxxinity shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is VAXX or NAVB more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Does the media favor VAXX or NAVB? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Vaxxinity Neutral Navidea Biopharmaceuticals Neutral SummaryVaxxinity and Navidea Biopharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25,000.00$6.49B$5.09B$8.79BDividend YieldN/A8.11%5.04%4.07%P/E Ratio0.005.3293.0914.02Price / Sales0.36370.921,220.6787.41Price / CashN/A52.5939.4936.27Price / Book0.0010.236.936.33Net Income-$56.93M$153.22M$118.83M$225.71M7 Day PerformanceN/A-1.99%-1.74%-0.58%1 Month PerformanceN/A-7.51%-3.60%1.49%1 Year PerformanceN/A31.02%31.91%27.23% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.00flatN/A-100.0%$25,000.00$70,000.000.0090NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.3%$100,000.00$70,000.000.0010CALACalithera BiosciencesN/A$0.01flatN/A-76.0%$35,000.00$9.75M0.0060SCPSScopus BioPharmaN/A$0.00flatN/A-99.3%$13,000.00N/A0.009AMPEAmpio PharmaceuticalsN/A$0.01+∞N/A-99.6%$11,000.00N/A0.0020Gap DownARDSAridis PharmaceuticalsN/AN/AN/AN/A$10,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A+0.0%$10,000.00$1.49M0.0020CMRAComera Life SciencesN/A$0.00flatN/A-99.5%$9,000.00$630,000.000.002EVLOEvelo BiosciencesN/A$0.00-66.7%N/A-99.7%$9,000.00N/A0.00120News CoverageGap DownGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastEFTReFFECTOR Therapeutics1.2787 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010Negative News Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Calithera Biosciences Competitors Scopus BioPharma Competitors Ampio Pharmaceuticals Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Comera Life Sciences Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VAXX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VAXX Stock Alerts